Mucus plugging, air trapping, and bronchiectasis are important outcome measures in assessing progressive childhood cystic fibrosis lung disease
Robinson, Terry E; Goris, Michael L; Moss, Richard B; Tian, Lu; Kan, Peiyi; Yilma, Mignote; McCoy, Karen S; Newman, Beverley; de Jong, Pim A; Long, Frederick R; Brody, Alan S; Behrje, Rhett; Yates, Denise P; Cornfield, David N
(2020) Pediatric Pulmonology, volume 55, issue 4, pp. 929 - 938
(Article)
Abstract
OBJECTIVE: To determine which outcome measures could detect early progression of disease in school-age children with mild cystic fibrosis (CF) lung disease over a two-year time interval utilizing chest computed tomography (CT) scores, quantitative CT air trapping (QAT), and spirometric measurements. METHODS: Thirty-six school-age children with mild CF lung disease
... read more
(median [interquartile range] age 12 [3.7] years; percent predicted forced expiratory volume in 1 second (ppFEV1 ) 99 [12.5]) were evaluated by serial spirometer-controlled chest CT scans and spirometry at baseline, 3-month, 1- and 2-years. RESULTS: No significant changes were noted at 3-month for any variable except for decreased ppFEV1 . Mucus plugging score (MPS) and QATA1andA2 increased at 1- and 2-years. The bronchiectasis score (BS), and total score (TS) were increased at 2-year. All variables tested with the exception of bronchial wall thickness score, parenchymal score (PS), and ppFEV1 , were consistent with longitudinal worsening of lung disease. Multivariate analysis revealed baseline PS, baseline TS, and 1-year changes in BS and air trapping score were predictive of 2-year changes in BS. CONCLUSIONS: MPS and QATA1-A2 were the most sensitive indicators of progressive childhood CF lung disease. The 1-year change in the bronchiectasis score had the most positive predictive power for 2-year change in bronchiectasis.
show less
Download/Full Text
The full text of this publication is not available.
Keywords: chest CT scoring, cystic fibrosis, quantitative air trapping, spirometry, Pulmonary and Respiratory Medicine, Pediatrics, Perinatology, and Child Health, Journal Article
ISSN: 8755-6863
Publisher: Wiley-Liss Inc.
Note: Funding Information: TER received a research grant and MLG, KSM, PAD, FRL, and ASB also received funding from Novartis Institutes for Biomedical Research. DPY is a Novartis restricted stock shareholder. RBM, LT, PK, MY, B.N, RB, DY, and DNC have not declared conflict of interests. Publisher Copyright: © 2020 Wiley Periodicals, Inc. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.
(Peer reviewed)